NDAVAGINALAEROSOL
Approved
Dec 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DELFEN is a nonoxynol-9 vaginal aerosol contraceptive that has been on the market since 1963. It is a spermicide used for pregnancy prevention and functions as a non-hormonal barrier contraceptive option. The product serves women seeking an over-the-counter contraceptive method without systemic hormonal effects.
LOE Approaching
Product is approaching loss of exclusivity with minimal commercial momentum; expect small, maintenance-focused teams rather than growth-oriented staffing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study of Nonoxynol-9 (N-9) and HIV Infection
4,400 enrolled
HIV Infections
Career Relevance
DELFEN currently has zero linked job openings, reflecting its mature, legacy status in the contraceptive market. Career opportunities on this product are limited to maintenance and compliance roles rather than growth or innovation-focused positions.
Brand Manager
Worked on DELFEN at Personal Genomics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.